

China Technology

OUTPERFORM
 (Maintain)

Implications of UMC 3Q23: inventory correction, UTR/margin under pressure, PC & smartphone rush order

UMC posted in-line 3Q23 results on strong computing/communication and better product mix. Looking ahead, mgmt. expects PC & smartphone inventory recovery but auto correction will persist into 2024. In addition, mgmt. expects 8-inch UTR and ASP to be under pressure but positive on 12-inch and specialty process demand. Overall, we believe investors will start to focus on PC/smartphone recovery in 4Q23/2024E. For stocks, we recommend to focus on Luxshare (002475 CH), Q-tech (1478 HK) and Sunny Optical (2382 HK), as well as Chinese foundries such as SMIC (981 HK) and Hua Hong (1347 HK).

- **3Q23 results in-line; strong computing/communication and better product mix.** UMC's 3Q revenue of -24%YoY/+1.4%QoQ is in-line with market expectation, driven by strong computing/communication segments, better product mix and favourable FX rate. Shipment decline of 2% QoQ but slight increase in ASP are in line with previous guidance. GPM of 35.9% is above consensus by 1.6ppts mainly on product mix.
- **Lower UTR in 4Q weighs on GPM.** Mgmt. guided 4Q wafer shipment to decline by ~5% QoQ but ASP will remain flat. UTR will be in the low-60% range compared with 67% in 3Q. Guided GPM is in the low 30% range which is slightly below consensus estimate of 34.4%.
- **PC& smartphone rush order and inventory recovery; auto inventory correction into 2024.** Mgmt. believes PC& smartphone demand gradually stabilized and expects rush orders in 4Q, which indicates an early sign of inventory recovery. However, automotive inventory is building up and mgmt. expects inventory correction will persist into 2024. In addition, industrial segment is better than auto given broad applications.
- **8-inch UTR/ASP under pressure; 12-inch solid demand.** Mgmt. expects 8-inch UTR and ASP to be under pressure given weak demand and intensified competition but 12-inch will focus on specialty process with solid demand and stable ASP. In addition, mgmt. reiterated that LTA is still intact with 25-30% coverage but is faced with adjustment in the short term. Looking into 2024, mgmt. expects UTR/shipment to grow YoY when cycle recovers.
- **Maintain FY23E capex; capacity expansion on track.** Mgmt. maintained FY23E capex guidance of US\$3bn and shared their capacity expansion plan: 1) P6 capacity to reach 12k in end 2023 and 32k in Sep 2024; 2) P3 Singapore capacity ramp up in Apr 2025.
- **Positive on smartphone supply chain.** Overall, we believe investors will start to focus on PC/smartphone recovery in 4Q23/2024E. We recommend to pay attention to names including Luxshare (002475 CH), Q-tech (1478 HK) and Sunny Optical (2382 HK), as well as Chinese foundries such as SMIC (981 HK) and Hua Hong (1347 HK).

Valuation Table

Name	Ticker	Mkt Cap (US\$ mn)	Price (LC)	P/E (x)		P/B (x)		ROE
				FY23E	FY24E	FY23E	FY23E	FY23E
SMIC	981 HK	21275	21.6	22.1	21.8	1.06	3.8	
Hua Hong Semi	1347 HK	4277	18.6	12.3	13.8	0.79	10.5	
TSMC	2330 TT	445537	544	17.8	14.7	4.09	24.8	
UMC	2303 TT	18815	49.1	10.8	10.5	1.81	16.6	

Source: Company data, CMBIGM estimates

China Technology Sector

Alex NG

(852) 3900 0881
alexng@cmbi.com.hk

Hanqing LI

lihanqing@cmbi.com.hk

Related Reports:

1. Implications of Texas Instruments 3Q23: weaker industrial, destocking and slower China recovery – 26 Oct 2023 ([link](#))
2. Implications of TSMC 3Q23: cycle nearing the bottom; Positive on smartphone/PC supply chain -24 Oct 2023 ([link](#))
3. Implications of ASML/LAM Research 3Q23 results - 20 Oct 2023 ([link](#))
4. Implications of US's updated chip export restrictions to global/ domestic SPE/GPU companies - 18 Oct 2023 ([link](#))
5. Global SPE 2Q23 Wrap: China demand remains resilient; Awaiting upcycle after 2023 slowdown - 18 Sep 2023 ([link](#))
6. Global fabless/IDM 2Q23 wrap: expect continued inventory correction for non-AI players; All eyes on NVDA 3Q23E guidance – 23 Aug 2023 ([link](#))
7. Global foundry 2Q23 Wrap: prolonged inventory correction; slower demand recovery in 2H-16 Aug 2023 ([link](#))

Key takeaways of UMC (2303 TT, NR) 3Q23 results:

1. 3Q23 Results

- Revenue: TWD57.069bn, -24.3% YoY/+1.4% QoQ, above consensus by 1.9%
- GPM: 35.9%, -11.4ppts YoY/-0.1ppts QoQ, above consensus by 1.6ppts due to product mix
- Net profit: TWD 15.971bn, -40.8% YoY/+2.1% YoY
- EPS: TWD 1.29, -40.1% YoY/+1.6% QoQ
- Blended ASP increased slightly in 3Q23
- Wafer shipment: declined by 2.3% QoQ
- UTR: 67% vs. 71% in 2Q23

2. 3Q23 sales breakdown

- Breakdown by technology
 - 14-28nm: 32% of sales, vs 29% in 2Q23
 - 28-40nm: 13% of sales, vs 12% in 2Q23
 - 40-65nm: 19% of sales, vs 23% in 2Q23
 - 65-90nm: 8% of sales, vs 10% in 2Q23
 - 90nm and above: 28% of sales, vs 26% in 2Q23
- Breakdown by application
 - Computer: 13% of sales, vs 9% in 2Q23
 - Communication: 46% of sales, vs 44% in 2Q23
 - Consumer: 23% of sales, vs 26% in 2Q23
 - Others: 18% of sales, vs 21% in 2Q23
- Breakdown by region
 - North America: 27% of sales, vs 27% in 2Q23
 - Asia Pacific: 58% of sales, vs 56% in 2Q23
 - Europe: 12% of sales, vs 12% in 2Q23
 - Japan: 3% of sales, vs 5% in 2Q23


3. 4Q23 Guidance

- Wafer shipment: decline by ~5% QoQ
- ASP: remain flat in USD
- GPM: in the low-30% range
- UTR: low-60% range
- 2023 Capex: US\$3bn unchanged

4. Other highlight


- Rush order from PC& smartphone in 4Q; auto inventory correction into 2024; industrial better than auto
- 8-inch UTR and ASP under pressure; 12-inch strong demand and stable ASP
- LTA:25-30%, intact but face adjustment in the short term
- 2024 outlook: UTR/Shipment YoY growth but focus on quarterly performance
- New capacity: P6 of 12 by end 2023 and 32k by Sep 2024; P3 capacity ramp-up in Apr 2025
- Capex: FY23E capex of US\$ 3bn remains unchanged

Figure 1: UMC: revenue by application 3Q23




Source: Company data, CMBIGM estimates

Figure 2: UMC: revenue by region 3Q23



Source: Company, CMBIGM estimates

Figure 3: UMC: revenue by customer type 3Q23



Source: Company data, CMBIGM estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.